Lowest Price Guaranteed From USD 4,799
Published
September 2023
Slides
120
View Count
1361
Example Insights
Please scroll down
Report Description
The global market for the next generation drug conjugates is expected to grow at a compounded annual growth rate (CAGR) of more than 20% during the forecast period. The next generation drug conjugates, owing to their non-immunogenic nature, better clinical profile, structural stability, limited side effects, targeted delivery of payload, deeper cellular penetration, and permeability, have emerged as the viable targeted therapeutics for rare disease indications, including cancers. Over the last decade, the standard cost of medical care for rare disease indications has increased exponentially. Specifically, in the US, close to USD 1 trillion was spent for medical care for rare diseases in 2020. Further, the average cost incurred by a patient suffering from a rare disease condition was USD 60,248 in 2020, which if taken into account is twice the average cost incurred by any general patient. The incremental rise in medicare cost, coupled with the rising burden of rare disease indications globally, prompted the stakeholders to look for alternatives to the conventional therapies, and next generation drug conjugates have emerged as a promising treatment option.
Owing to the structural similarity with antibody drug conjugates (ADCs), and various advantages related to clinical efficacy and stability over ADCs, the next generation drug conjugates have emerged as its direct viable alternative. Similar to ADCs, the next generation drug conjugates utilize a targeting ligand, a linker and a payload for the targeted delivery. However, unlike ADCs, which use antibody as the targeting ligand, the next generation drug conjugates utilize various non-antibody-based targeting ligands, such as peptides, amino sugar, lipid, and small molecule as their targeting agent. Further, in place of drug, it utilizes oligonucleotide, antisense oligonucleotide, si-RNA, drug, and radionuclide as their payload.
As a result of various synergistic combinations with the targeting ligand and payload, various types of next generation drug conjugates, such as peptide drug conjugate, peptide receptor radionuclide therapy (peptide radionuclide conjugate), GalNac conjugates, peptide oligonucleotide conjugate, si-RNA conjugate, small molecule-drug conjugate (SMDC), ligand conjugated anti sense medicine (LICA), and peptide conjugated phosphorodiamidate morpholino oligomers (PPMO) have emerged in the domain of targeted therapeutics. The success of these next generation drug conjugates can be attributed to their clinical effectiveness, and its ability to target wide range of therapeutic modalities, including solid tumors, multiple myeloma, metabolic disorders, and hematological disorders. Till date, six next generation drug conjugates have been approved by the USFDA for therapeutic purposes, which include Lutathera® and Pluvicto®, peptide receptor radionuclide therapy, developed by Advanced Accelerator Applications, and Givlaari®, Oxlumo®, Leqvio® and Amvuttra® (GalNac conjugates) developed by Alnylam Pharmaceuticals.
With the ongoing pace of innovation in this field, encouraging clinical trial results, accelerated approvals, and the continuous efforts of both industry and non-industry players, the next generation drug conjugates market is likely to witness significant growth during the forecast period.
![]() |
![]() |
![]() |
![]() |
The Next Generation Drug Conjugates Market: Focus on GalNac Conjugate, Peptide Drug Conjugate, Peptide Oligonucleotide Conjugate, RNAi Conjugate, Peptide Receptor Radionuclide Therapy, Small Molecule-Drug Conjugate (SMDC), and Other Conjugates – Distribution by Type of Targeting Ligand (Amino Sugar, Lipid, Peptide, Small Molecule and Virus-like Particles), Type of Payload (Peptide, Small Molecule, Oligonucleotide and Radionuclide), Type of Therapy (Monotherapy and Combination Therapy), Route of Administration (Intravenous, Subcutaneous and Others), Mechanism of Action (sequence-specific target binding, radiation induced cytotoxicity, cancer-specific surface target mediated cytotoxicity, drug induced cytotoxicity, receptor mediated internalization and cytotoxicity and others) and Key Target Indications (Gastroenteropancreatic Neuroendocrine Tumors, Prostate Cancer, Leptomeningeal Carcinomatosis caused by Breast Cancer Brain Metastases, Hereditary Transthyretin Amyloidosis, Atherosclerotic Cardiovascular Diseases, Severe Hypertriglyceridemia, Hereditary Angioedema, Acute Hepatic Porphyria, Primary Hyperoxaluria, Heterozygous Familial Hypercholesterolemia, Hemophilia, Low-Risk Myelodysplastic Syndrome, Myelofibrosis, Alpha-1 Antitrypsin Deficiency Liver Disease and Familial Chylomicronemia Syndrome) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunities in the next generation drug conjugates market, during the given forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the next generation drug conjugates market are briefly discussed below.
The next generation drug conjugates market landscape is concentrated with the presence of over 30 large, mid-sized and small players engaged in the development of next generation drug conjugates. Currently, over 200 next generation drug conjugates are either approved or being evaluated in various stages of clinical research; of these, more than 50% of the drug candidates are in preclinical / discovery phase.
It is worth highlighting that close to 40% and 30% of the drug candidates are being investigated for the treatment of oncological and rare diseases, respectively, in different phases of development. These drug candidates have emerged as a promising targeted therapy. Further, over 260 clinical trials focused on various next generation drug conjugates, such as small molecule-drug conjugates (SMDC), peptide drug conjugates, GalNac conjugates, and others have been conducted since 2018, indicating the substantial efforts made by researchers engaged in this industry.
Breakthrough in the pharmaceutical industry in the last few years has led to the development of various new types of drug modalities. Next Generation Drug Conjugates are one of the many new drug modalities, which have surfaced as targeted therapies for rare disorders and oncological disorders. Interestingly, owing to their structure and mechanism of action, peptide drug conjugate have emerged as a possible alternative to the antibody drug conjugates. Pepaxto, developed by Oncopeptides was the first anticancer peptide drug conjugate to receive accelerated approval from the FDA for the treatment of relapsed or refractory multiple myeloma in February 2021. However, the drug was withdrawn from the US market in October 2021 due to unfavorable results in a phase III clinical trial.
In American Society of Clinical Oncology (ASCO) 2023 annual meeting, clinical trial results of two peptide drug conjugate were presented, which include preliminary results from phase I clinical trials of Cybrexa Therapeutics / Exelixis’ CBX-12 and Theratechnologies’ TH1902. Additionally, there are about 10 peptide drug conjugate candidates, which are being evaluated either as monotherapy or combination therapy in active clinical trials. Further, it is worth highlighting that UK based Bicycle Therapeutics is leading the development of this novel drug class. In February 2023, Bicycle Therapeutics presented results from phase I portion of an ongoing phase I/II clinical trial of BT8009 under development for the treatment of heavily pre-treated urothelial, lung and breast cancer patients. In January 2023. the company received fast track designation from the FDA for BT8009 as a monotherapy for the treatment of adult patients with previously treated locally advanced or metastatic urothelial cancer. As the peptide drug conjugates move along the clinical development trajectory, we expect the market to grow at a favorable CAGR during the forecast period.
Peptide receptor radionuclide therapy (PRRT) candidates comprise of an antigen targeting peptide conjugated to a radioisotope / radionuclide through a linker. Novartis is currently the market leader in PRRT therapy (peptide radionuclide conjugate) market with two marketed products – Lutathera and Pluvicto. Pluvicto, received FDA and EMA approval for the treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer patients who have already been treated with other anticancer treatments in March 2022 and December 2022, respectively. Novartis recorded sales worth USD 271 million for Pluvicto in FY 2022, even though there was a supply shortage reported for the drug in the US.
With its continuous focus on research on PRRT therapy (peptide radionuclide conjugates) market, Novartis signed a collaboration agreement with Bicycle Therapeutics in March 2023 for the development of bicycle radio-conjugates, which are peptide receptor radionuclide therapy using bicyclic peptides. Later in May 2023, Bayer entered into a similar collaboration with Bicycle Therapeutics for development of peptide radioconjugates targeting cancer. There have been more such partnerships and collaborations in this emerging segment of the drug conjugates market. Looking at the successful uptake of the approved PRRT therapy candidates and the rising interest of big pharma in the PRRT therapy market, this segment will continue to witness significant market growth during the forecast period.
Over the past decade, oligonucleotide therapeutics have emerged as a promising therapeutic modality. Within these, the GalNAc conjugates have recently emerged as a breakthrough therapy for various rare disorders. GalNAc conjugates comprise of N-acetylgalactosamine (GalNAc) sugar molecule conjugated to an oligonucleotide. Given the affinity of GalNAc molecules to attach with the asialoglycoprotein receptor (ASGPR) of the liver cells, the GalNAc conjugated oligonucleotide therapy emerged as the dominant strategy for delivering therapeutic modality through the liver cells.
Ionis, Alnylam, Dicerna, and Suzhou Ribo Life Science are the key players involved in the development of GalNAc-conjugated oligonucleotide therapies. Amongst these players, Alnylam Pharmaceuticals has emerged as the market leader with four marketed products: Givlaari, Oxlumo, Leqvio, and Amvuttra. However, it is worth mentioning that the recent acquisition of Dicerna by Novo Nordisk in November 2021 and Ionis' collaboration with pharma giant AstraZeneca in April 2023 have increased interest among stakeholders and big pharma players in this domain. With at least 12 drug candidates from Ionis, Dicerna, and Alnylam, anticipated to receive approval in the coming years, and a robust pipeline of 21 drug candidates by Suzhou Ribo Life Sciences, it is anticipated that the segment will continue to witness significant market growth during the forecasted period.
A number of stakeholders are forging alliances with other industry / non-industry players. In fact, over 75 strategic partnerships related to next generation drug conjugates, have been signed since 2018. Close to 45% of the partnerships inked in this domain are product development and commercialization agreements, indicating the efforts of stakeholders in development and commercialization of these next generation drug conjugates. It is worth highlighting that, owing to the recent increase in activity in this domain, many big pharma players have shown keen interest in entering this domain. For instance, companies such as Novartis, AstraZeneca, Janssen and others have forged strategic partnerships with these next generation drug conjugate developers, in order to gain entry into this domain.
![]() |
![]() |
![]() |
![]() |
With the ongoing research efforts for the development of next generation drug conjugates, and growing contribution of big pharma players, we believe that the next generation drug conjugates market is likely to evolve at a rapid pace, over the forecast period.
Driven by the increasing number of R&D activities and growing demand for effective therapies for rare and oncological disorders, the next generation drug conjugates market is anticipated to witness an annualized growth rate (CAGR) of over more than 20%, during the period 2023-2035. Specifically, in terms of type of conjugates, the global market for next generation drug conjugates is anticipated to be driven by the GalNac Conjugates. Likewise, in terms of therapeutic area, the market is anticipated to be dominated by the conjugates targeting rare and oncological disorders.
In addition to it, more than 70% market share is captured by the players based in North America, of which ~60% are based in the US. This is followed by Asia-Pacific where a number of developers are engaged in the development of next generation drug conjugates. Interestingly, within Asia-Pacific, China has emerged as the leading country where majority of the next generation drug conjugate developers are based.
The recent accelerated approvals of various next generation drug conjugates, such as peptide drug conjugates, GalNac conjugates, and conjugates utilizing peptide radionuclide therapy (peptide radionuclide conjugate), along with the grant of orphan and breakthrough designations by the regulatory authorities, such as the USFDA and the EMA, has increased the overall interest and confidence of the pharmaceutical industry in these novel targeted therapies. All the above factors will contribute to a healthy market growth of the next generation drug conjugates market during the forecast period.
Examples of key players engaged in next generation drug conjugate development (which have also been captured in this report, arranged in alphabetical order) include Advanced Accelerator Applications, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Cellectar Biosciences, Dicerna Pharmaceuticals, Ionis Pharmaceuticals, Shenzhen Ascentawits Pharmaceuticals Sirnaomics, Silence Therapeutics, and Suzhou Ribo Life Science. This market report includes an easily searchable excel database of all the next generation drug conjugate companies worldwide.
Several recent developments have taken place in the field of next generation drug conjugates market, some of which have been outlined below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we have outlined in our analysis.
The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments, as defined in the below table:
Key Report Attributes | Details | |
Base Year |
2022 |
|
Forecast Period |
2023 – 2035 |
|
CAGR | 20% | |
Type of Next Generation Drug Conjugates |
|
|
Type of Targeting Ligand |
|
|
Type of Payload |
|
|
Type of Therapy |
|
|
Route of Administration |
|
|
Target Indications |
|
|
Key Companies Profiled |
|
|
Customization Scope | 15% Free Customization Option | |
PowerPoint Presentation (Complimentary) | Available | |
Excel Data Packs (Complimentary) |
|
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market report includes:
One of the key objectives of this market report was to estimate the current market size and the future growth potential of the next generation drug conjugates over the forecast period. Based on several parameters, such as target consumer segments, region-specific adoption rates, and expected prices of such products, we have developed informed estimates of the likely evolution of the next generation drug conjugates market over the forecast period 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as type of conjugate (peptide receptor radionuclide therapy, ligand mediated RNAi conjugates, ligand conjugates anti sense medicine and peptide drug conjugates), key target indications (gastroenteropancreatic neuroendocrine tumors, prostate cancer, leptomeningeal carcinomatosis caused by breast cancer brain metastases, hereditary transthyretin amyloidosis, atherosclerotic cardiovascular diseases, severe hypertriglyceridemia, hereditary angioedema, acute hepatic porphyria, primary hyperoxaluria, heterozygous familial hypercholesterolemia, hemophilia, low-risk myelodysplastic syndrome, myelofibrosis, alpha-1 antitrypsin deficiency liver disease and familial chylomicronemia syndrome), and key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and secondary research. Financial figures mentioned in this report are in USD, unless otherwise specified.
![]() |
![]() |
![]() |
Contents
1. PREFACE
1.1. Next Generation Drug Conjugates Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Next Generation Drug Conjugates
3.2. Key Historical Events
3.3. Structure of Next Generation Drug Conjugates
3.4. Biochemical Interaction and Mechanism of Action
3.5. Key Target Indications
3.6. Advantages of Next Generation Drug Conjugates
3.7 Challenges associated with Next Generation Drug Conjugates
3.8. Future Perspectives
4. MARKET LANDSCAPE
4.1. Methodology
4.2. Next Generation Drug Conjugates: List of Therapies
4.2.1. Analysis by Type of Conjugate
4.2.2. Analysis by Type of Targeting Ligand
4.2.3. Analysis by Type of Payload
4.2.4. Analysis by Biological Target
4.2.5. Analysis by Mechanism of Action
4.2.6. Analysis by Stage of Development
4.2.7. Analysis by Phase of Development
4.2.8. Analysis by Type of Therapy
4.2.9. Analysis by Route of Administration
4.2.10. Analysis by Target Disease Indication
4.2.11. Analysis by Therapeutic Area
4.2.12. Analysis by Target Population
4.2.13. Analysis by Type of Conjugate and Stage of Development
4.2.14. Analysis by Type of Conjugate and Target Populatio
4.3 Next Generation Drug Conjugates: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters (Region-wise)
4.3.4. Analysis by Location of Headquarters (Country-wise)
4.3.5. Analysis by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
4.3.6. Most Active Players: Analysis by Number of Drug Candidates
5. COMPANY AND DRUG PROFILES
5.1. Advanced Accelerator Applications
5.1.1. Company Overview
5.1.2. Management Team
5.1.3. Product Portfolio
5.1.3.1. Lutathera®
5.1.3.1.1 Drug Overview
5.1.3.1.2. Clinical Trial Information
5.1.3.1.3. Clinical Trial Results
5.1.3.1.4. Dosing Regimen
5.1.3.1.5. Estimated Sales
5.1.3.2. Pluvicto®
5.1.3.2.1 Drug Overview
5.1.3.2.2. Clinical Trial Information
5.1.3.2.3. Clinical Trial Results
5.1.3.2.4. Dosing Regimen
5.1.3.2.5. Estimated Sales
5.1.4. Recent Developments and Future Outlook
5.2. Alnylam Pharmaceuticals
5.2.1. Company Overview
5.2.2. Management Team
5.2.3. Product Portfolio
5.2.3.1. Givlaari®
5.2.3.1.1. Drug Overview
5.2.3.1.2. Clinical Trial Information
5.2.3.1.3. Clinical Trial Results
5.2.4.1.4. Dosing Regimen
5.2.3.2. Oxlumo®
5.2.3.2.1. Drug Overview
5.2.3.2.2. Clinical Trial Information
5.2.3.2.3. Clinical Trial Results
5.2.3.2.4. Dosing Regimen
5.2.3.3. Leqvio®
5.2.3.3.1. Drug Overview
5.2.3.3.2. Clinical Trial Information
5.2.3.3.3. Clinical Trial Results
5.2.3.3.4. Dosing Regimen
5.2.3.4. Amvuttra®
5.2.3.4.1. Drug Overview
5.2.3.4.2. Clinical Trial Information
5.2.3.4.3. Clinical Trial Results
5.2.3.4.4. Dosing Regimen
5.2.4. Recent Developments and Future Outlook
5.3. Arrowhead Pharmaceuticals
5.3.1. Company Overview
5.3.2. Management Team
5.3.3. Product Portfolio
5.3.3.1. Olpasiran
5.3.3.1.1. Drug Overview
5.3.3.1.2. Clinical Trial Information
5.3.3.1.3. Clinical Trial Results
5.3.3.1.4. Dosing Regimen
5.3.3.2. ARO-AAT
5.3.3.2.1. Drug Overview
5.3.3.2.2. Clinical Trial Information
5.3.3.2.3. Clinical Trial Results
5.3.3.2.4. Dosing Regimen
5.3.3.3. ARO-APOC3
5.3.3.3.1. Drug Overview
5.3.3.3.2. Clinical Trial Information
5.3.3.3.3. Clinical Trial Results
5.3.3.3.4. Dosing Regimen
5.3.4. Recent Developments and Future Outlook
5.4. Dicerna Pharmaceuticals
5.4.1. Company Overview
5.4.2. Management Team
5.4.3. Product Portfolio
5.4.3.1. Nedosiran
5.4.3.1.1 Drug Overview
5.4.3.1.2. Clinical Trial Information
5.4.3.1.3. Clinical Trial Results
5.4.3.1.4. Dosing Regimen
5.4.4. Recent Developments and Future Outlook
5.5. Geron
5.5.1. Company Overview
5.5.2. Management Team
5.5.3. Product Portfolio
5.5.3.1. Imtelstat
5.5.3.1.1. Drug Overview
5.5.3.1.2. Clinical Trial Information
5.5.3.1.3. Clinical Trial Results
5.5.3.1.4. Dosing Regimen
5.5.4. Recent Developments and Future Outlook
5.6. Ionis Pharmaceuticals
5.6.1. Company Overview
5.6.2. Management Team
5.6.3. Product Portfolio
5.6.3.1. Eplontersen
5.6.3.1.1 Drug Overview
5.6.3.1.2. Clinical Trial Information
5.6.3.1.3. Clinical Trial Results
5.6.3.1.4. Dosing Regimen
5.6.3.2. Olezarsen
5.6.3.2.1. Drug Overview
5.6.3.2.2. Clinical Trial Information
5.6.3.2.3. Clinical Trial Results
5.6.3.2.4. Dosing Regimen
5.6.3.3. Pelacarsen
5.6.3.3.1. Drug Overview
5.6.3.3.2. Clinical Trial Information
5.6.3.3.3. Clinical Trial Results
5.6.3.3.4. Dosing Regimen
5.6.3.3.5. Estimated Sales
5.6.3.4. Donidalorsen
5.6.3.4.1 Drug Overview
5.6.3.4.2. Clinical Trial Information
5.6.3.4.3. Clinical Trial Results
5.6.3.4.4. Dosing Regimen
5.6.4. Recent Developments and Future Outlook
6. CLINICAL TRIAL ANALYSIS
6.1. Analysis Methodology and Key Parameters
6.2. Next Generation Drug Conjugates: Clinical Trial Analysis
6.2.1. Analysis by Trial Registration Year
6.2.2. Analysis by Trial Phase
6.2.3. Analysis by Trial Status
6.2.4. Analysis by Therapeutic Area
6.2.5. Analysis by Primary Purpose
6.2.6. Analysis by Age Group
6.2.7. Analysis by Type of Sponsor
6.2.8. Most Active Industry Players: Analysis by Number of Trials
6.2.9. Leading Drug Candidates: Analysis by Number of Trials
6.2.10. Analysis by Trial Registration Year and Trial Location
6.2.11. Analysis by Trial Registration Year and Enrolled Patient Population
6.2.12. Analysis by Trial Phase and Enrolled Patient Population
6.2.13. Analysis by Trial Status and Enrolled Patient Population
6.2.14. Analysis by Trial Location and Enrolled Patient Population
6.2.15. Analysis by Trial Status and Trial Location
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Partnership Models
7.2. Next Generation Drug Conjugates: Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Type of Partner
7.3.5. Analysis by Year of Partnership and Type of Partner
7.3.6. Analysis by Type of Partnership and Type of Partner
7.3.7. Analysis by Type of Partner and Parent Company Size
7.3.8. Analysis by Therapeutic Area
7.3.9. Most Active Players: Analysis by Number of Partnerships
7.3.10. Analysis by Geography
7.3.10.1. Analysis by Type of Geography (Region-wise)
7.3.10.2. Analysis by Type of Geography (Country-wise)
7.3.10.3. Intercontinental and Intracontinental Agreements
8. ACADEMIC GRANTS ANALYSIS
8.1. Methodology and Key Parameters
8.2. Next Generation Drug Conjugates: Academic Grants Analysis
8.2.1. Analysis by Year of Grant Award
8.2.2. Analysis by Amount Awarded
8.2.3. Analysis by Funding Institute Center
8.2.4. Analysis by Support Period
8.2.5. Analysis by Funding Institute Center and Support Period
8.2.6. Analysis by Type of Grant Application
8.2.7. Analysis by Purpose of Grant
8.2.8. Analysis by Activity Code
8.2.9. Analysis by Study Section
8.2.10. Popular NIH Departments: Analysis by Number of Grants
8.2.11. Analysis by Type of Recipient Organization
8.2.11.1. Popular Recipient Organizations: Analysis by Number of Grants
8.2.11.2. Popular Recipient Organizations: Analysis by Amount Awarded
8.2.12. Prominent Program Officers: Analysis by Number of Grants
8.2.13 Analysis by Location of Recipient Organizations
9. PUBLICATION ANALYSIS
9.1. Analysis Methodology and Key Parameters
9.2. Next Generation Drug Conjugates: Publication Analysis
9.2.1. Analysis by Year of Publication
9.2.2. Analysis by Type of Publication
9.2.3. Analysis by Type of Conjugate
9.2.4. Analysis by Target Indication
9.2.5. Analysis by Copyright Holder
9.2.6. Word Cloud: Emerging Focus Area
9.2.7. Most Active Publishers: Analysis by Number of Publications
9.2.8. Key Journals: Analysis by Number of Publications
9.2.9. Key Journals: Analysis by Impact Factor
10. DRUG FAILURE ANALYSIS
10.1. Analysis Methodology and Key Parameters
10.2. Next Generation Drug Conjugates: Drug Failure Analysis
10.2.1. Analysis by Status of Discontinuation
10.2.2. Analysis by Phase of Discontinuation
10.2.3. Analysis by Average Trial Year
10.2.4. Analysis by Type of Therapy
10.2.5. Analysis by Target Indication
10.2.6. Analysis by Reason for Drug Failure
11. SUCCESS PROTOCOL ANALYSIS
11.1. Methodology and Key Parameters
11.2. Key Assumptions and Scoring Criteria
11.3. Success Protocol Analysis
11.4. Assessment of Approved Next Generation Drug Conjugates: Harvey Ball Analysis
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Key Assumptions and Forecast Methodology
12.2. Next Generation Drug Conjugates Market, 2023-2035
12.2.1. Next Generation Drug Conjugates Market: Distribution by Type of Conjugate, 2023 and 2035
12.2.1.1. Next Generation Drug Conjugates Market for Peptide Radionuclide Conjugates, 2023-2035
12.2.1.2. Next Generation Drug Conjugates Market for Ligand Conjugated Anti Sense Medicine, 2023-2035
12.2.1.3. Next Generation Drug Conjugates Market for Ligand Mediated RNAi Conjugates, 2023-2035
12.2.1.4. Next Generation Drug Conjugates Market for Peptide Drug Conjugates, 2023-2035
12.2.2. Next Generation Drug Conjugates Market: Distribution by Targeting Ligand
12.2.2.1 Next Generation Drug Conjugates Market for Amino Sugars, 2023-2035
12.2.2.2 Next Generation Drug Conjugates Market for Peptides, 2023-2035
12.2.2.3 Next Generation Drug Conjugates Market for Lipids, 2023-2035
12.2.3. Next Generation Drug Conjugates Market: Distribution by Payload
12.2.3.1. Next Generation Drug Conjugates Market for Radionuclides, 2023-2035
12.2.3.2. Next Generation Drug Conjugates Market for Drugs, 2023-2035
12.2.3.3. Next Generation Drug Conjugates Market for Antisense Oligonucleotides, 2023-2035
12.2.3.4 Next Generation Drug Conjugates Market for si-RNAs, 2023-2035
12.2.4. Next Generation Drug Conjugates Market: Distribution by Therapy
12.2.4.1. Next Generation Drug Conjugates Market for Monotherapy, 2023-2035
12.2.4.2. Next Generation Drug Conjugates Market for Combination Therapy, 2023-2035
12.2.5. Next Generation Drug Conjugates Market: Distribution by Route of Administration
12.2.5.1. Next Generation Intravenous Drug Conjugates Market, 2023-2035
12.2.5.2. Next Generation Subcutaneous Drug Conjugates Market, 2023-2035
12.2.6. Next Generation Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035
12.2.6.1. Next Generation Drug Conjugates Market for Gastroenteropancreatic Neuroendocrine Tumors, 2023-2035
12.2.6.2. Next Generation Drug Conjugates Market for Prostate Cancer, 2023-2035
12.2.6.3. Next Generation Drug Conjugates Market for Leptomeningeal Carcinomatosis caused by Breast Cancer Brain Metastases, 2023-2035
12.2.6.4. Next Generation Drug Conjugates Market for Hereditary Transthyretin Amyloidosis, 2023-2035
12.2.6.5. Next Generation Drug Conjugates Market for Atherosclerotic Cardiovascular Diseases, 2023-2035
12.2.6.6. Next Generation Drug Conjugates Market for Severe Hypertriglyceridemia, 2023-2035
12.2.6.7. Next Generation Drug Conjugates Market for Hereditary Angioedema, 2023-2035
12.2.6.8. Next Generation Drug Conjugates Market for Acute Hepatic Porphyria, 2023-2035
12.2.5.9. Next Generation Drug Conjugates Market for Primary Hyperoxaluria, 2023-2035
12.2.5.10. Next Generation Drug Conjugates Market for Heterozygous Familial Hypercholesterolemia, 2023-2035
12.2.5.11. Next Generation Drug Conjugates Market for Hemophilia, 2023-2035
12.2.5.12. Next Generation Drug Conjugates Market for Low-Risk Myelodysplastic Syndrome, 2023-2035
12.2.5.13. Next Generation Drug Conjugates Market for Myelofibrosis, 2023-2035
12.2.5.14. Next Generation Drug Conjugates Market for Alpha-1 Antitrypsin Deficiency Liver Disease, 2023-2035
12.2.5.15. Next Generation Drug Conjugates Market for Familial Chylomicronemia Syndrome, 2023-2035
12.2.6. Next Generation Drug Conjugates Market: Distribution by Key Geographical Regions, 2023 and 2035
12.2.6.1. Next Generation Drug Conjugates Market in North America, 2023-2035
12.2.6.1.1. Next Generation Drug Conjugates Market in the US, 2022-2035
12.2.6.1.2. Next Generation Drug Conjugates Market in Canada, 2022-2035
12.2.6.2. Next Generation Drug Conjugates Market in Europe, 2023-2035
12.2.6.2.1. Next Generation Drug Conjugates Market in the UK, 2022-2035
12.2.6.2.2. Next Generation Drug Conjugates Market in France, 2022-2035
12.2.6.2.3. Next Generation Drug Conjugates Market in Germany, 2022-2035
12.2.6.2.4. Next Generation Drug Conjugates Market in Spain, 2022-2035
12.2.6.2.5. Next Generation Drug Conjugates Market in Italy, 2022-2035
12.2.6.2.6. Next Generation Drug Conjugates Market in Rest of the Europe, 2022-2035
12.2.6.3. Next Generation Drug Conjugates Market in Asia-Pacific and Rest of the World, 2023-2035
12.2.6.3.1. Next Generation Drug Conjugates Market in Japan, 2023-2035
12.2.6.3.2. Next Generation Drug Conjugates Market in Australia, 2023-2035
12.2.6.3.3. Next Generation Drug Conjugates Market in Brazil, 2023-2035
12.3. Next Generation Drug Conjugates Market: Product-wise Sales Forecast, 2023-2035
12.3.1. Lutathera®
12.3.1.1. Sales Forecast (USD Million)
12.3.1.2. Net Present Value (USD Million)
12.3.1.3. Value Creation Analysis
12.3.2. Pluvicto®
12.3.2.1. Sales Forecast (USD Million)
12.3.2.2. Net Present Value (USD Million)
12.3.2.3. Value Creation Analysis
12.3.3. Givlaari®
12.3.3.1. Sales Forecast (USD Million)
12.3.3.2. Net Present Value (USD Million)
12.3.3.3. Value Creation Analysis
12.3.4. Oxlumo®
12.3.4.1. Sales Forecast (USD Million)
12.3.4.2. Net Present Value (USD Million)
12.3.4.3. Value Creation Analysis
12.3.5. Leqvio®
12.3.5.1. Sales Forecast (USD Million)
12.3.5.2. Net Present Value (USD Million)
12.3.5.3. Value Creation Analysis
12.3.6. Amvuttra®
12.3.6.1. Sales Forecast (USD Million)
12.3.6.2. Net Present Value (USD Million)
12.3.6.3. Value Creation Analysis
12.3.7. Eplontersen
12.3.7.1. Sales Forecast (USD Million)
12.3.7.2. Net Present Value (USD Million)
12.3.7.3. Value Creation Analysis
12.3.8. Olezarsen
12.3.8.1. Sales Forecast (USD Million)
12.3.8.2. Net Present Value (USD Million)
12.3.8.3. Value Creation Analysis
12.3.9. Pelacarsen
12.3.9.1. Sales Forecast (USD Million)
12.3.9.2. Net Present Value (USD Million)
12.3.9.3. Value Creation Analysis
12.3.10. Donidalorsen
12.3.10.1. Sales Forecast (USD Million)
12.3.10.2. Net Present Value (USD Million)
12.3.10.3. Value Creation Analysis
12.3.11. Fitusiran
12.3.11.1. Sales Forecast (USD Million)
12.3.11.2. Net Present Value (USD Million)
12.3.11.3. Value Creation Analysis
12.3.12. Nedosiran
12.3.12.1. Sales Forecast (USD Million)
12.3.12.2. Net Present Value (USD Million)
12.3.12.3. Value Creation Analysis
12.3.13. Imetlestat
12.3.13.1. Sales Forecast (USD Million)
12.3.13.2. Net Present Value (USD Million)
12.3.13.3. Value Creation Analysis
12.3.14. Olpasiran
12.3.14.1. Sales Forecast (USD Million)
12.3.14.2. Net Present Value (USD Million)
12.3.14.3. Value Creation Analysis
12.3.15. ARO-AAT
12.3.15.1. Sales Forecast (USD Million)
12.3.15.2. Net Present Value (USD Million)
12.3.15.3. Value Creation Analysis
12.3.16. ARO-APOC3
12.3.16.1. Sales Forecast (USD Million)
12.3.16.2. Net Present Value (USD Million)
12.3.16.3. Value Creation Analysis
12.3.17. ANG-1005
12.3.17.1. Sales Forecast (USD Million)
12.3.17.2. Net Present Value (USD Million)
12.3.17.3. Value Creation Analysis
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1. Key Historical Events
Figure 3.2. Structure of Next Generation Drug Conjugates
Figure 3.3. Biochemical Interaction and Mechanism of Action
Figure 3.4. Key Target Indications
Figure 4.1 Next Generation Drug Conjugates: Distribution by Type of Conjugate
Figure 4.2. Next Generation Drug Conjugates: Distribution by Type of Targeting Ligand
Figure 4.3. Next Generation Drug Conjugates: Distribution by Type of Payload
Figure 4.4. Next Generation Drug Conjugates: Distribution by Biological Target
Figure 4.5. Next Generation Drug Conjugates: Distribution by Mechanism of Action
Figure 4.6. Next Generation Drug Conjugates: Distribution by Stage of Development
Figure 4.7. Next Generation Drug Conjugates: Distribution by Phase of Development
Figure 4.8. Next Generation Drug Conjugates: Distribution by Type of Therapy
Figure 4.9. Next Generation Drug Conjugates: Distribution by Route of Administration
Figure 4.10. Next Generation Drug Conjugates: Distribution by Target Disease Indication
Figure 4.11. Next Generation Drug Conjugates: Distribution by Therapeutic Area
Figure 4.12. Next Generation Drug Conjugates: Distribution by Target Population
Figure 4.13. Next Generation Drug Conjugates: Distribution by Type of Conjugate and Stage of Development
Figure 4.14. Next Generation Drug Conjugates: Distribution by Type of Conjugate and Target Population
Figure 4.15. Next Generation Drug Conjugate Developers: Distribution by Year of Establishment
Figure 4.16. Next Generation Drug Conjugate Developers: Distribution by Company Size
Figure 4.17. Next Generation Drug Conjugate Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.18. Next Generation Drug Conjugate Developers: Distribution by Location of Headquarters (Country-wise)
Figure 4.19. Next Generation Drug Conjugate Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
Figure 4.20. Most Active Players: Distribution by Number of Drug Candidates
Figure 6.1. Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 6.2. Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.3. Clinical Trial Analysis: Distribution by Trial Status
Figure 6.4. Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 6.5. Clinical Trial Analysis: Distribution by Primary Purpose
Figure 6.6. Clinical Trial Analysis: Distribution by Age Group
Figure 6.7. Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 6.8. Most Active Industry Players: Distribution by Number of Trials
Figure 6.9. Leading Drug Candidates: Distribution by Number of Trials
Figure 6.10. Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Location
Figure 6.11. Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 6.12. Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
Figure 6.13. Clinical Trial Analysis: Distribution by Trial Status and Enrolled Patient Population
Figure 6.14. Clinical Trial Analysis: Distribution by Trial Location and Enrolled Patient Population
Figure 6.15. Clinical Trial Analysis: Distribution by Trial Status and Trial Location
Figure 7.1. Partnerships and Collaborations: Distribution by Year of Partnership
Figure 7.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4. Partnerships and Collaborations: Distribution by Type of Partner
Figure 7.5. Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 7.6. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 7.7. Partnerships and Collaborations: Distribution by Type of Partner and Parent Company Size
Figure 7.8. Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 7.9. Most Active Players: Distribution by Number of Partnerships
Figure 7.10. Partnerships and Collaborations: Distribution by Type of Geography (Region-wise)
Figure 7.11. Partnerships and Collaborations: Distribution by Type of Geography (Country-wise)
Figure 7.12. Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 8.1. Academic Grants Analysis: Distribution by Year of Grant Award
Figure 8.2. Academic Grants Analysis: Distribution by Amount Awarded
Figure 8.3. Academic Grants Analysis: Distribution by Funding Institute Center
Figure 8.4. Academic Grants Analysis: Distribution by Support Period
Figure 8.5. Academic Grants Analysis: Distribution by Funding Institute Center and Support Period
Figure 8.6. Academic Grants Analysis: Distribution by Type of Grant Application
Figure 8.7. Academic Grants Analysis: Distribution by Purpose of Grant
Figure 8.8. Academic Grants Analysis: Distribution by Activity Code
Figure 8.9. Academic Grants Analysis: Distribution by Study Section
Figure 8.10 Popular NIH Departments: Distribution by Number of Grants
Figure 8.12. Popular Recipient Organization: Distribution by Number of Grants
Figure 8.13. Popular Recipient Organization: Distribution by Amount Awarded
Figure 8.14 Prominent Program Officers: Distribution by Number of Grants
Figure 8.15. Academic Grants Analysis: Distribution by Location of Recipient Organizations
Figure 9.1. Publication Analysis: Distribution by Year of Publication
Figure 9.2. Publication Analysis: Distribution by Type of Publication
Figure 9.3. Publication Analysis: Distribution by Type of Conjugate
Figure 9.4. Publication Analysis: Distribution by Target Indication
Figure 9.5. Publication Analysis: Distribution by Copyright Holder
Figure 9.6. Word Cloud: Emerging Focus Area
Figure 9.7. Most Active Publishers: Distribution by Number of Publications
Figure 9.8. Key Journals: Distribution by Number of Publications
Figure 9.9. Key Journals: Distribution by Impact Factor
Figure 10.1. Drug Failure Analysis: Distribution by Status of Discontinuation
Figure 10.2. Drug Failure Analysis: Distribution by Phase of Discontinuation
Figure 10.3. Drug Failure Analysis: Distribution by Average Trial Year
Figure 10.4. Drug Failure Analysis: Distribution by Type of Therapy
Figure 10.5. Drug Failure Analysis: Distribution by Target Indication
Figure 10.6. Drug Failure Analysis: Distribution by Reason for Drug Failure
Figure 11.1. Success Protocol Analysis: Lutathera (Gastroenteropancreatic Neuroendocrine Tumor)
Figure 11.2. Success Protocol Analysis: Pluvicto® (Prostate Cancer)
Figure 11.3. Success Protocol Analysis: Givlaari® (Acute Hepatic Porphyria)
Figure 11.4 Success Protocol Analysis: Oxlumo® (Primary Hyperoxaluria)
Figure 11.5 Success Protocol Analysis: Amvuttra® (Hereditary ATTR Amyloidosis)
Figure 11.6 Success Protocol Analysis: Leqvio® (Heterozygous Familial Hypercholesterolemia)
Figure 11.7 Success Protocol Analysis: Overall Assessment of Approved Next Generation Drug Conjugates
Figure 12.1. Global Next Generation Drug Conjugates Market, 2023-2035 (USD Million)
Figure 12.2. Next Generation Drug Conjugates Market: Distribution by Type of Conjugate, 2023 and 2035 (USD Million)
Figure 12.3. Next Generation Drug Conjugates Market for Peptide Radionuclide Conjugates, 2023-2035 (USD Million)
Figure 12.4. Next Generation Drug Conjugates Market for Ligand Conjugated Anti Sense Medicine, 2023-2035 (USD Million)
Figure 12.5 Next Generation Drug Conjugates Market for Ligand mediated RNAi Conjugates, 2023-2035 (USD Million)
Figure 12.6. Next Generation Drug Conjugates Market for Peptide Drug Conjugates, 2023-2035 (USD Million)
Figure 12.7. Next Generation Drug Conjugates Market: Distribution by Targeting Ligand, 2023 and 2035 (USD Million)
Figure 12.8. Next Generation Drug Conjugates Market for Amino Sugars, 2023-2035 (USD Million)
Figure 12.9 Next Generation Drug Conjugates Market for Peptides, 2023-2035 (USD Million)
Figure 12.10. Next Generation Drug Conjugates Market for Lipids, 2023-2035 (USD Million)
Figure 12.11. Next Generation Drug Conjugates Market: Distribution by Payload, 2023 and 2035 (USD Million)
Figure 12.12. Next Generation Drug Conjugates Market for Radionuclides, 2023-2035 (USD Million)
Figure 12.13. Next Generation Drug Conjugates Market for Drugs, 2023-2035 (USD Million)
Figure 12.14. Next Generation Drug Conjugates Market for Antisense Oligonucleotides, 2023-2035 (USD Million)
Figure 12.15. Next Generation Drug Conjugates Market for si-RNAs, 2023-2035 (USD Million)
Figure 12.16. Next Generation Drug Conjugates Market: Distribution by Therapy, 2023 and 2035 (USD Million)
Figure 12.17 Next Generation Drug Conjugates Market for Monotherapy, 2023-2035 (USD Million)
Figure 12.18. Next Generation Drug Conjugates Market for Combination Therapy 2023-2035 (USD Million)
Figure 12.19 Next Generation Drug Conjugates Market: Distribution by Route of Administration, 2023 and 2035 (USD Million)
Figure 12.20. Next Generation Intravenous Drug Conjugates Market, 2023-2035 (USD Million)
Figure 12.21. Next Generation Subcutaneous Drug Conjugates Market, 2023-2035 (USD Million)
Figure 12.22. Next Generation Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035 (USD Million)
Figure 12.23. Next Generation Drug Conjugates Market for Gastroenteropancreatic Neuroendocrine Tumors, 2023-2035 (USD Million)
Figure 12.24. Next Generation Drug Conjugates Market for Prostate Cancer, 2023-2035 (USD Million)
Figure 12.25. Next Generation Drug Conjugates Market for Leptomeningeal Carcinomatosis, 2023-2035 (USD Million)
Figure 12.26. Next Generation Drug Conjugates Market for Hereditary Transthyretin Amyloidosis, 2023-2035 (USD Million)
Figure 12.27. Next Generation Drug Conjugates Market for Atherosclerotic Cardiovascular Diseases, 2023-2035 (USD Million)
Figure 12.28. Next Generation Drug Conjugates Market for Severe Hypertriglyceridemia, 2023-2035 (USD Million)
Figure 12.29. Next Generation Drug Conjugates Market for Hereditary Angioedema, 2023-2035 (USD Million)
Figure 12.30. Next Generation Drug Conjugates Market for Acute Hepatic Porphyria, 2023-2035 (USD Million)
Figure 12.31. Next Generation Drug Conjugates Market for Primary Hyperoxaluria, 2023-2035 (USD Million)
Figure 12.32. Next Generation Drug Conjugates Market for Heterozygous Familial Hypercholesterolemia, 2023-2035 (USD Million)
Figure 12.33. Next Generation Drug Conjugates Market for Hemophilia, 2023-2035 (USD Million)
Figure 12.34. Next Generation Drug Conjugates Market for Low-Risk Myelodysplastic Syndrome, 2023-2035 (USD Million)
Figure 12.35. Next Generation Drug Conjugates Market for Myelofibrosis, 2023-2035 (USD Million)
Figure 12.36. Next Generation Drug Conjugates Market for Alpha-1 Antitrypsin Deficiency Liver Disease, 2023-2035 (USD Million)
Figure 12.37. Next Generation Drug Conjugates Market for Familial Chylomicronemia Syndrome, 2023-2035 (USD Million)
Figure 12.38. Next Generation Drug Conjugates Market: Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Figure 12.39. Next Generation Drug Conjugates Market in North America, 2023-2035 (USD Million)
Figure 12.40. Next Generation Drug Conjugates Market in the US, 2023-2035 (USD Million)
Figure 12.41. Next Generation Drug Conjugates Market in Canada, 2023-2035 (USD Million)
Figure 12.42. Next Generation Drug Conjugates Market in Europe, 2023-2035 (USD Million)
Figure 12.43. Next Generation Drug Conjugates Market in the UK, 2023-2035 (USD Million)
Figure 12.44. Next Generation Drug Conjugates Market in France, 2023-2035 (USD Million)
Figure 12.45. Next Generation Drug Conjugates Market in Germany, 2023-2035 (USD Million)
Figure 12.46. Next Generation Drug Conjugates Market in Spain, 2023-2035 (USD Million)
Figure 12.47. Next Generation Drug Conjugates Market in Italy, 2023-2035 (USD Million)
Figure 12.48. Next Generation Drug Conjugates Market in Rest of the Europe, 2023-2035 (USD Million)
Figure 12.49. Next Generation Drug Conjugates Market in Asia-Pacific and Rest of the World, 2023-2035 (USD Million)
Figure 12.50. Next Generation Drug Conjugates Market in Japan, 2023-2035 (USD Million)
Figure 12.51. Next Generation Drug Conjugates Market in Australia, 2023-2035 (USD Million)
Figure 12.52. Next Generation Drug Conjugates Market in Brazil, 2023-2035 (USD Million)
Figure 12.53. Lutathera®: Sales Forecast (USD Million)
Figure 12.54. Pluvicto®: Sales Forecast (USD Million)
Figure 12.55. Givlaari®: Sales Forecast (USD Million)
Figure 12.56. Oxlumo®: Sales Forecast (USD Million)
Figure 12.57. Leqvio®: Sales Forecast (USD Million)
Figure 12.58. Amvuttra®: Sales Forecast (USD Million)
Figure 12.59. Eplontersen: Sales Forecast (USD Million)
Figure 12.60. Olezarsen: Sales Forecast (USD Million)
Figure 12.61. Pelacarsen: Sales Forecast (USD Million)
Figure 12.62. Donidalorsen: Sales Forecast (USD Million)
Figure 12.63. Fitusiran: Sales Forecast (USD Million)
Figure 12.64. Nedosiran: Sales Forecast (USD Million)
Figure 12.65. Imetlestat: Sales Forecast (USD Million)
Figure 12.66. Olpasiran: Sales Forecast (USD Million)
Figure 12.67. ARO-AAT: Sales Forecast (USD Million)
Figure 12.68. ARO-APOC3: Sales Forecast (USD Million)
Figure 12.69. ANG-1005: Sales Forecast (USD Million)
Table 4.1. Next Generation Drug Conjugates: List of Therapies
Table 4.2. Next Generation Drug Conjugates: List of Developers
Table 5.1. Advance Accelerator Applications: Product Portfolio
Table 5.2. Lutathera®: Drug Overview
Table 5.3. Lutathera®: Clinical Trial Information
Table 5.4 Lutathera®: Dosing Regimen
Table 5.5 Pluvicto®: Drug Overview
Table 5.6 Pluvicto®: Clinical Trial Information
Table 5.7 Pluvicto®: Dosing Regimen
Table 5.8 Advance Accelerator Applications: Recent Developments and Future Outlook
Table 5.9. Alnylam Pharmaceuticals: Product Portfolio
Table 5.10. Givlaari®: Drug Overview
Table 5.11. Givlaari®: Clinical Trial Information
Table 5.12 Givlaari®: Dosing Regimen
Table 5.13. Oxlumo®: Drug Overview
Table 5.14. Oxlumo®: Clinical Trial Information
Table 5.15 Oxlumo®: Dosing Regimen
Table 5.16. Leqvio®: Drug Overview
Table 5.17. Leqvio®: Clinical Trial Information
Table 5.18. Leqvio®: Dosing Regimen
Table 5.19. Amvuttra®: Drug Overview
Table 5.20. Amvuttra®: Clinical Trial Information
Table 5.21. Amvuttra®: Dosing Regimen
Table 5.22. Alnylam Pharmaceuticals: Recent Developments and Future Outlook
Table 5.23. Arrowhead Pharmaceuticals: Product Portfolio
Table 5.24. Olapsiran: Drug Overview
Table 5.25. Olpasiran: Clinical Trial Information
Table 5.26 Olapsiran: Dosing Regimen
Table 5.27. ARO-AAT: Drug Overview
Table 5.28. ARO-AAT: Clinical Trial Information
Table 5.29 ARO-AAT: Dosing Regimen
Table 5.30. ARO-APOC3: Drug Overview
Table 5.31. ARO-APOC3: Clinical Trial Information
Table 5.32 ARO-APOC3: Dosing Regimen
Table 5.33. Arrowhead Pharmaceuticals: Recent Developments and Future Outlook
Table 5.34. Dicerna Pharmaceuticals: Product Portfolio
Table 5.35. Nedosiran: Drug Overview
Table 5.36. Nedosiran: Clinical Trial Information
Table 5.37 Nedosiran: Dosing Regimen
Table 5.38. Dicerna Pharmaceuticals: Recent Developments and Future Outlook
Table 5.39. Geron: Product Portfolio
Table 5.40. Imtelstat: Drug Overview
Table 5.41. Imtelstat: Clinical Trial Information
Table 5.42 Imtelstat: Dosing Regimen
Table 5.43. Geron: Recent Developments and Future Outlook
Table 5.44. Ionis Pharmaceuticals: Product Portfolio
Table 5.45. Eplontersen (Transthyretin-Mediated Amyloidosis – Polyneuropathy): Drug Overview
Table 5.46. Eplontersen (Transthyretin-Mediated Amyloidosis – Polyneuropathy): Clinical Trial Information
Table 5.47 Eplontersen (Transthyretin-Mediated Amyloidosis – Polyneuropathy): Dosing Regimen
Table 5.48. Eplontersen (Transthyretin-Mediated Amyloidosis – Cardiomyopathy): Drug Overview
Table 5.49. Eplontersen (Transthyretin-Mediated Amyloidosis – Cardiomyopathy): Clinical Trial Information
Table 5.50. Eplontersen (Transthyretin-Mediated Amyloidosis – Cardiomyopathy): Dosing Regimen
Table 5.51. Olezarsen: Drug Overview
Table 5.52. Olezarsen: Clinical Trial Information
Table 5.53. Olezarsen: Dosing Regimen
Table 5.54. Pelacarsen: Drug Overview
Table 5.55. Pelacarsen: Clinical Trial Information
Table 5.56. Pelacarsen: Dosing Regimen
Table 5.57. Donidalorsen: Drug Overview
Table 5.58. Donidalorsen: Clinical Trial Information
Table 5.59. Donidalorsen: Dosing Regimen
Table 5.60. Ionis Pharmaceuticals: Recent Developments and Future Outlook
Table 6.1. Next Generation Drug Conjugates: List of Clinical Trials (Sample Data, Pre-2017-2023)
Table 7.1. Next Generation Drug Conjugates: List of Partnerships and Collaborations (2018-2023)
Table 8.1. Next Generation Drug Conjugates: List of Academic Grants (Sample Data, Pre-2021-2023)
Table 9.1. Next Generation Drug Conjugates: List of Publications (Sample Data, 2018-2023)
Table 10.1. Next Generation Drug Conjugates: List of Failed Drugs
Table 12.1. Next Generation Drug Conjugates Market: List of Forecasted Drugs
Table 13.1 Next Generation Drug Conjugates: Distribution by Type of Conjugate
Table 13.2. Next Generation Drug Conjugates: Distribution by Type of Targeting Ligand
Table 13.3. Next Generation Drug Conjugates: Distribution by Type of Payload
Table 13.4. Next Generation Drug Conjugates: Distribution by Biological Target
Table 13.5. Next Generation Drug Conjugates: Distribution by Mechanism of Action
Table 13.6. Next Generation Drug Conjugates: Distribution by Stage of Development
Table 13.7. Next Generation Drug Conjugates: Distribution by Phase of Development
Table 13.8. Next Generation Drug Conjugates: Distribution by Type of Therapy
Table 13.9. Next Generation Drug Conjugates: Distribution by Route of Administration
Table 13.10. Next Generation Drug Conjugates: Distribution by Target Disease Indication
Table 13.11. Next Generation Drug Conjugates: Distribution by Therapeutic Area
Table 13.12. Next Generation Drug Conjugates: Distribution by Target Population
Table 13.13. Next Generation Drug Conjugates: Distribution by Type of Conjugate and Stage of Development
Table 13.14. Next Generation Drug Conjugates: Distribution by Type of Conjugate and Target Population
Table 13.15. Next Generation Drug Conjugate Developers: Distribution by Year of Establishment
Table 13.16. Next Generation Drug Conjugate Developers: Distribution by Company Size
Table 13.17. Next Generation Drug Conjugate Developers: Distribution by Location of Headquarters (Region-wise)
Table 13.18. Next Generation Drug Conjugate Developers: Distribution by Location of Headquarters (Country-wise)
Table 13.19. Next Generation Drug Conjugate Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
Table 13.20. Most Active Players: Distribution by Number of Drug Candidates
Table 13.21. Clinical Trial Analysis: Distribution by Trial Registration Year
Table 13.22. Clinical Trial Analysis: Distribution by Trial Phase
Table 13.23. Clinical Trial Analysis: Distribution by Trial Status
Table 13.24. Clinical Trial Analysis: Distribution by Therapeutic Area
Table 13.25. Clinical Trial Analysis: Distribution by Primary Purpose
Table 13.26. Clinical Trial Analysis: Distribution by Age Group
Table 13.27. Clinical Trial Analysis: Distribution by Type of Sponsor
Table 13.28. Most Active Industry Players: Analysis by Number of Trials
Table 13.29. Leading Drug Candidates: Analysis by Number of Trials
Table 13.30. Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Location
Table 13.31. Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 13.32. Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
Table 13.33. Clinical Trial Analysis: Distribution by Trial Status and Enrolled Patient Population
Table 13.34. Clinical Trial Analysis: Distribution by Trial Location and Enrolled Patient Population
Table 13.35. Clinical Trial Analysis: Distribution by Trial Status and Trial Location
Table 13.36. Partnerships and Collaborations: Distribution by Year of Partnership
Table 13.37. Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.38. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 13.39. Partnerships and Collaborations: Distribution by Type of Partner
Table 13.40. Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 13.41. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 13.42. Partnerships and Collaborations: Distribution by Type of Partner and Parent Company Size
Table 13.43. Partnerships and Collaborations: Distribution by Therapeutic Area
Table 13.44. Most Active Players: Analysis by Number of Partnerships
Table 13.45. Partnerships and Collaborations: Distribution by Type of Geography (Region-wise)
Table 13.46. Partnerships and Collaborations: Distribution by Type of Geography (Country-wise)
Table 13.47. Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 13.48. Academic Grants Analysis: Distribution by Year of Grant Award
Table 13.49. Academic Grants Analysis: Distribution by Amount Awarded
Table 13.50 Academic Grants Analysis: Distribution by Funding Institute Center
Table 13.51. Academic Grants Analysis: Distribution by Support Period
Table 13.52. Academic Grants Analysis: Distribution by Funding Institute Center and Support Period
Table 13.53. Academic Grants Analysis: Distribution by Type of Grant Application
Table 13.54. Academic Grants Analysis: Distribution by Purpose of Grant
Table 13.55. Academic Grants Analysis: Distribution by Activity Code
Table 13.56. Academic Grants Analysis: Distribution by Study Section
Table 13.57 Popular NIH Departments: Analysis by Number of Grants
Table 13.58. Popular Recipient Organizations: Distribution by Number of Grants
Table 13.59. Popular Recipient Organizations: Distribution by Amount Awarded
Table 13.60 Prominent Program Officers: Analysis by Number of Grants
Table 13.61. Academic Grants Analysis: Distribution by Location of Recipient Organizations
Table 13.62. Publication Analysis: Distribution by Year of Publication
Table 13.63. Publication Analysis: Distribution by Type of Publication
Table 13.64. Publication Analysis: Distribution by Type of Conjugate
Table 13.65. Publication Analysis: Distribution by Target Indication
Table 13.66. Publication Analysis: Distribution by Copyright Holder
Table 13.67. Word Cloud: Emerging Focus Area
Table 13.68. Most Active Publishers: Analysis by Number of Publications
Table 13.69. Key Journals: Analysis by Number of Publications
Table 13.70. Key Journals: Analysis by Impact Factor
Table 13.71. Drug Failure Analysis: Distribution by Status of Discontinuation
Table 13.72. Drug Failure Analysis: Distribution by Phase of Discontinuation
Table 13.73. Drug Failure Analysis: Distribution by Average Trial Year
Table 13.74. Drug Failure Analysis: Distribution by Type of Therapy
Table 13.75. Drug Failure Analysis: Distribution by Target Indication
Table 13.76 Drug Failure Analysis: Distribution by Reason of Drug Failure
Table 13.77. Global Next Generation Drug Conjugates Market, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.78. Next Generation Drug Conjugates Market: Distribution by Type of Conjugate, 2023 and 2035 (USD Million)
Table 13.79. Next Generation Drug Conjugates Market for Peptide Radionuclide Conjugates, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.80. Next Generation Drug Conjugates Market for Ligand Conjugated Anti Sense Medicines, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.81. Next Generation Drug Conjugates: Distribution for Ligand mediated RNAi Conjugates, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.82. Next Generation Drug Conjugates Market for by Peptide Drug Conjugates, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.83. Next Generation Drug Conjugates Market: Distribution by Targeting Ligand, 2023 and 2035 (USD Million)
Table 13.84. Next Generation Drug Conjugates Market: Distribution for Amino Sugars, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.85. Next Generation Drug Conjugates Market for Peptides, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.86. Next Generation Drug Conjugates Market for Lipids, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.87. Next Generation Drug Conjugates Market: Distribution by Payload, Conservative, Base and Optimistic Scenarios, 2023 and 2035 (USD Million)
Table 13.88. Next Generation Drug Conjugates Market for Radionuclides, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.89. Next Generation Drug Conjugates Market for Drugs, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.90. Next Generation Drug Conjugates Market for Antisense Oligonucleotides, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.91. Next Generation Drug Conjugates Market for si-RNAs, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.92. Next Generation Drug Conjugates Market: Distribution by Type of Therapy, 2023 and 2035 (USD Million)
Table 13.93. Next Generation Drug Conjugates Market for Monotherapy, Conservative, Base and Optimistic Scenario, 2023 and 2035 (USD Million)
Table 13.94. Next Generation Drug Conjugates Market for Combination Therapy, Conservative, Base and Optimistic Scenario, 2023 and 2035 (USD Million)
Table 13.95. Next Generation Drug Conjugates Market: Distribution by Route of Administration, 2023 and 2035 (USD Million)
Table 13.96. Next Generation Intravenous Drug Conjugates Market, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.947 Next Generation Subcutaneous Drug Conjugates Market, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.98. Next Generation Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035 (USD Million)
Table 13.99. Next Generation Drug Conjugates Market for Gastroenteropancreatic Neuroendocrine Tumors, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.100. Next Generation Drug Conjugates Market for Prostate Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.101. Next Generation Drug Conjugates Market for Leptomeningeal Carcinomatosis, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.102. Next Generation Drug Conjugates Market for Hereditary Transthyretin Amyloidosis, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.103. Next Generation Drug Conjugates Market for Atherosclerotic Cardiovascular Diseases, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.104. Next Generation Drug Conjugates Market for Severe Hypertriglyceridemia, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.105. Next Generation Drug Conjugates Market for Hereditary Angioedema, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.106. Next Generation Drug Conjugates Market for Acute Hepatic Porphyria, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.107. Next Generation Drug Conjugates Market for Primary Hyperoxaluria, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.108. Next Generation Drug Conjugates Market for Heterozygous Familial Hypercholesterolemia, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.109. Next Generation Drug Conjugates Market for Hemophilia, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.110. Next Generation Drug Conjugates Market for Low-Risk Myelodysplastic Syndrome, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.111. Next Generation Drug Conjugates Market for Myelofibrosis, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.112. Next Generation Drug Conjugates Market for Alpha-1 Antitrypsin Deficiency Liver Disease, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.113. Next Generation Drug Conjugates Market for Familial Chylomicronemia Syndrome, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.114. Next Generation Drug Conjugates Market: Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Table 13.115. Next Generation Drug Conjugates Market in North America, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.116. Next Generation Drug Conjugates Market in the US, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.117. Next Generation Drug Conjugates Market in Canada, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.118. Next Generation Drug Conjugates Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.119. Next Generation Drug Conjugates Market in the UK, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.120. Next Generation Drug Conjugates Market in France, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.121. Next Generation Drug Conjugates Market in Germany, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.122. Next Generation Drug Conjugates Market in Spain, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.123. Next Generation Drug Conjugates Market in Italy, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.124. Next Generation Drug Conjugates Market in Rest of the Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.125. Next Generation Drug Conjugates Market in Asia-Pacific and Rest of the World, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.126. Next Generation Drug Conjugates Market in Japan, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.127. Next Generation Drug Conjugates Market in Australia, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.128. Next Generation Drug Conjugates Market in Brazil, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.129. Lutathera®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.130. Pluvicto®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.131. Givlaari®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.132. Oxlumo®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.133. Leqvio®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.134. Amvuttra®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.135. Eplontersen: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.136. Olezarsen: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.137. Pelacarsen: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.138. Donidalorsen: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.139. Fitusiran: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.140. Nedosiran: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.141. Imetlestat: Sales Forecast, Conservative, Base and Optimistic Scenarios, 20232035 (USD Million)
Table 13.142. Olpasiran: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.143. ARO-AAT: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.144. ARO-APOC3: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.145. ANG-1005: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Source 1: https://www.pharmaceutical-technology.com/news/3bp-novartis-fap-targeting/
Source 2: https://everylifefoundation.org/wp-content/uploads/2021/02/The_National_Economic_Burden_of_Rare_Disease_Study_Infographic_February_2021.pdf